News & Articles

FEATURED ARTICLE

MASP2 Antibody Successful in Phase III Clinical Trial

On December 19, 2024, Omeros announced that its pivotal Phase 3 clinical trial of the MASP2 antibody Narsoplimab (OMS721) in the treatment of TA-TMA (Transplant-Associated Thrombotic Microangiopathy) met its primary endpoint of overall survival (OS), with a 3-fold reduction in mortality risk [1]. Omeros stock surged 37% after the press release...

Browse articles by topic:

Case Study: KACTUS T7 RNA Polymerase Enzyme Demonstrates Superior Performance in Independent Study

February 7, 2025

4 min read

Background The production of high-quality mRNA is critical for a wide range of applications, including gene therapy, vaccine development, and...

The Ideal Choice for Low dsRNA: MaxPure™ T7 RNA Polymerase

July 16, 2024

7 min read

Exciting news of mRNA vaccine research against monkeypox has been coming out since the beginning of 2024: February 15, the...

Engineered T7 RNA Polymerase to Reduce dsRNA

May 24, 2023

1 min read

Our Chief Technology Officer, ManHee Suh, recently presented at the NextGen RNA Summit in Boston, MA his talk on "Engineered...

Full Portfolio of In Vitro mRNA Synthesis Enzymes Submitted to FDA Drug Master Files (DMF)

April 23, 2023

2 min read

Contact us to request a quote or test sample!   Following the filings of our GMP-Grade BsaI and GMP-Grade T7...

BsaI and T7 RNA Polymerase of KACTUS Pass FDA DMF Filing

January 4, 2023

2 min read

After successful completion of DMF filings for our CRISPR Cas9 enzyme and Maxnuclease in the first half of 2022, we...

Have questions? Get in touch!

support@kactusbio.us